Last updated: March 2026
Exemestane (Aromasin) is a steroidal aromatase inhibitor that permanently destroys aromatase enzymes — no rebound when stopped. Its androgenic structure offers better lipid profiles than non-steroidal AIs, making it the bodybuilding community's preferred choice for PCT and cycle estrogen control.
Exemestane is a steroidal, irreversible aromatase inhibitor. Unlike anastrozole/letrozole which just block the enzyme, exemestane permanently destroys it — requiring new enzyme synthesis to restore aromatization.
Exemestane binds irreversibly to aromatase (CYP19A1), permanently inactivating the enzyme. The body must synthesize new aromatase to restore estrogen production. This takes 2-3 days, providing sustained suppression and no E2 rebound.
Unlike non-steroidal AIs, exemestane has an androstene backbone. This gives it mild androgenic properties and a better lipid profile. Some users report subjective androgenic effects — though not pronounced.
When anastrozole is stopped, blocked aromatase immediately becomes active → E2 spikes. With exemestane, destroyed enzymes can't rebound. E2 only returns as new enzymes are made. Key advantage for PCT.
Exemestane absorption increases ~40% when taken with a high-fat meal. Always take with food for consistent effect. This is different from anastrozole which has stable absorption regardless of food.
Data from breast cancer trials and comparative AI studies.
Exemestane dosing for TRT, PCT, and on-cycle estrogen control.
| Protocol | Dose | Frequency | Notes |
|---|---|---|---|
| TRT E2 Control | 12.5mg | 2x/week | Start low. Take with fat. Adjust based on sensitive E2 labs. |
| TRT High Aromatizer | 12.5-25mg | EOD | Some need more. Monitor labs every 6 weeks initially. |
| PCT Protocol | 12.5-25mg | EOD | No rebound = ideal for PCT. Combine with tamoxifen/clomiphene. |
| On-Cycle Control | 12.5-25mg | EOD | For aromatizing cycles. Adjust to symptoms + labs. |
| Breast Cancer (Reference) | 25mg | Daily | FDA-approved indication. After 2-3 years of tamoxifen. |
How exemestane compares to other aromatase inhibitors.
No rebound. Better lipids. Take with fat. 12.5-25mg.
Most prescribed. Rebound possible. May interact with tamoxifen.
99%+ suppression. Reversible. Easy to crash E2. Fertility use.
Important interactions to consider when using exemestane.
Unlike anastrozole, exemestane has NO known interaction with tamoxifen. This makes it the preferred AI for PCT protocols that combine AI + SERM. Safe to stack.
Primary use case. Exemestane handles aromatization from both exogenous testosterone and HCG-stimulated intratesticular production. Adjust dose to labs.
Strong CYP3A4 inducers (rifampin, phenytoin) can decrease exemestane levels by ~45%. May need dose adjustment if on these medications.
Do not combine with estrogen or HRT — defeats the purpose. Exemestane blocks estrogen production; adding exogenous estrogen is counterproductive.
Primary research supporting exemestane's clinical use.
Switching to exemestane after 2-3 years of tamoxifen significantly improved disease-free survival in ER+ breast cancer. Foundation for sequential AI use.
PMID: 15317891 →Exemestane 25mg/day increased testosterone 60% and bioavailable testosterone 56% in healthy young men. Also increased IGF-1 levels. Demonstrates HPG axis effects.
PMID: 12788888 →Exemestane had less negative impact on lipid profile compared to letrozole. HDL decreased less with exemestane, likely due to its androgenic structure.
PMID: 15520068 →Support supplements for AI users.
Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.
This page is for educational purposes only. It is not medical advice. Exemestane is a prescription medication. Use for estrogen management should be under physician supervision with regular monitoring. Always consult a qualified healthcare provider.